Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name PF-07257876
Synonyms
Therapy Description

PF-07257876 is a bispecific antibody that targets CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CD47 and PD-L1 (CD274) (NCI Thesaurus).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
PF-07257876 PF 07257876|PF07257876 CD47 Antibody 31 PD-L1 Inhibitor 14 PF-07257876 is a bispecific antibody that targets CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CD47 and PD-L1 (CD274) (NCI Thesaurus).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive Advanced Solid Tumor predicted - sensitive PF-07257876 Phase I Actionable In a Phase I trial, PF-07257876 treatment was well tolerated in patients with PD-L1 (CD274)-positive advanced solid tumors and resulted in an objective response rate of 5.6% (1/18, 1 partial response in a patient with head and neck squamous cell carcinoma) (J Clin Oncol 41, 2023 (suppl 16; abstr 2529); NCT04881045). detail...

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04881045 Phase I PF-07257876 Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. Completed USA | ESP 0


Additional content available in CKB BOOST